Antithrombotic therapy after femoropopliteal artery stenting: 12-month results from Japan Postmarketing Surveillance.

Osami KawaradaMichikazu NakaiKunihiro NishimuraHideki MiwaYusuke IwasakiDaitaro KannoTatsuya NakamaYoshito YamamotoNobuhiko OgataMasato NakamuraSatoshi Yasuda

Published in: Heart Asia (2019)

Clinical benefits of DAPT or cilostazol might be small in terms of TLR and MACCE at 12 months. Anticoagulation with warfarin at discharge might increase TLR at 12 months.

Keyphrases

atrial fibrillation
toll like receptor
antiplatelet therapy
inflammatory response
venous thromboembolism
immune response
direct oral anticoagulants
percutaneous coronary intervention
public health
oral anticoagulants
nuclear factor
acute coronary syndrome
stem cells
coronary artery disease
replacement therapy